Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trans NV-04
- Development stage
- Unknown
- Lead developer
- Kazia Therapeutics
- Modality
- Small Molecules
01
Overview
trans NV-04 is a small molecule drug developed as a cardiovascular agent. It has demonstrated significant reductions in blood pressure and arterial stiffness in preclinical and early clinical studies. The compound is also being researched for its potential as a kinase inhibitor in cancer treatment, though its primary development focus has been on cardiovascular diseases. The drug was initially developed by Novogen SAS[1][2][3][4].
- Other names
- trans-NV-04trans-NV04trans-NV 04NV-04NV04NV 04
Beyond the preview
Go deeper on trans NV-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trans NV-04.